# EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)

> **NIH NIH P30** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $287,368

## Abstract

Abstract - Early Phase Clinical Research Support (EPCRS) 
The Early Phase Clinical Research Support (EPCRS) provides critical resources for innovative short duration 
research protocols at UNC Lineberger Comprehensive Cancer Center (LCCC) in the form of skilled and 
specialized research coordinator, data management, and laboratory support. The trials supported by this 
resource are: complex with strong correlative science and/or pharmacokinetic and pharmacodynamic 
components; LCCC investigator-initiated; and primarily based on scientific expertise and interests of LCCC 
members. Trials are selected from among those submitted to the Protocol Office Executive Committee for 
review. Dr Claire Dees, EPCRS Faculty Director and co-leader, Clinical Research Program, in direct 
consultation with Drs. Carey (Associate Director, Clinical Sciences) and Hayes (co-leader, Clinical Research 
Program), makes the final selection. LCCC members conducted numerous innovative studies over the last five 
years including those: evaluating novel compounds with radiation; involving novel combinations; and 
incorporating novel correlative biomarkers and imaging. Many ECPRS supported trials originated in basic and 
preclinical science in UNC Lineberger laboratories. 
Since 2010, LCCC recruited a number of talented investigators actively growing our Phase I investigator 
initiated trial portfolio and so we anticipate expanded ECPRS use. In addition, the inaugural trials of the UNC 
immunotherapy center will begin in this cycle and will require additional specialized support. The first patients 
will be enrolled on UNC immunotherapy trials in the spring of 2016 and these initial trials would include patients 
with acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and multiple myeloma. 
The strong commitment of the UNC Lineberger leadership to the development of novel therapeutics as a 
Cancer Center strategic direction creates an environment that will generate even greater demand for 
specialized support.

## Key facts

- **NIH application ID:** 9834869
- **Project number:** 5P30CA016086-44
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** ELIZABETH CLAIRE DEES
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $287,368
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9834869

## Citation

> US National Institutes of Health, RePORTER application 9834869, EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020) (5P30CA016086-44). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9834869. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*